Breakthrough data released at the AARC Congress 2016 (San Antonio) reinforces Aerogen’s credentials as global leaders in high performance aerosol drug delivery.
This data conclusively demonstrates how introducing Aerogen Ultra to a busy Emergency Department can significantly improve throughput by reducing admissions and increasing discharges.
| |
| Summary |
| |
The study was a retrospective chart review involving treatment of 1576 patients over two consecutive months in the ED of a busy urban medical facility. Patients receiving aerosol bronchodilator treatments by traditional small volume jet nebulisers were compared with patients treated using Aerogen Ultra. Treatments were primarily for asthma (paediatric and adult) as well as chronic obstructive pulmonary disorder (COPD).
Dowland Study Poster
|
|
No hay comentarios:
Publicar un comentario